Bioresorbable scaffolds (BRS) were designed as an alternative to metallic stents with the goal of complete resorption to allow vascular remodelling and to decrease late clinical events associated with permanent implants1.
The DESolve® scaffold (Elixir Medical Corporation, Milpitas, CA, USA) is a next-generation scaffold with an early biodegradation and bioresorption profile that has demonstrated positive vascular remodelling at six months and favourable clinical outcomes2,3. The device is comprised of poly-L-lactic acid (PLLA) coated with a matrix of novolimus and a polylactide-based polymer. The strut thickness is 150 µm. We report the five-year clinical results with 18...
Sign in to read and download the full articleForgot your password?
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com